Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ASMB with free AI briefings, catalyst countdowns, and dilution alerts.

ASMB · Assembly Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$314.3M Cash on Hand
57.7mo Cash Runway
Follow ASMB by email Get an email when ASMB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ASMB, unsubscribe in one click. Privacy

📣 What ASMB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Nucleoside Reverse Transcriptase Inhibitor Chronic Hepatitis B Phase 2 · NCT04454567 Terminated
Entecavir Chronic Hepatitis B Phase 2 · NCT04781647 Terminated
AB-729 Chronic Hepatitis B Phase 2 · NCT04820686 Terminated
Peg-IFNα Chronic Hepatitis B Phase 2 · NCT04781647 Terminated
ABI-H2158 Chronic Hepatitis B Phase 2 · NCT04398134 Terminated
Vebicorvir Chronic Hepatitis B Phase 2 · NCT04781647 Terminated
ABI-6250 Chronic Hepatitis D Infection Phase 2 · NCT07762027 Not yet recruiting
Esomeprazole Chronic Hepatitis B Phase 1 · NCT04142762 Completed
Nucleos(t)ide Chronic Hepatitis B Phase 1 · NCT02908191 Completed
Ethinyl Estradiol/Levonorgestrel Chronic Hepatitis B Phase 1 · NCT04142762 Completed
ABI-M201 Ulcerative Colitis Chronic Mild Phase 1 · NCT03923478 Terminated
ABI-H3733 Solid Oral Dosage Form Chronic Hepatitis B Phase 1 · NCT04271592 Completed
ABI-H3733 Liquid Oral Dosage Form Chronic Hepatitis B Phase 1 · NCT04271592 Completed
ABI-H3733 Chronic Hepatitis B Phase 1 · NCT05414981 Completed
ABI-H2158 Test Formulation Chronic Hepatitis B Phase 1 · NCT04083716 Completed
ABI-H2158 Reference Formulation Chronic Hepatitis B Phase 1 · NCT04083716 Completed

Also used in these trials (approved or third-party drugs, not ASMB's own candidates): Peginterferon Alfa-2A, Tenofovir Disoproxil Fumarate, Rifampin, Midazolam Hydrochloride, Itraconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ASMB holds $314.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $16.3M/quarter from operations, an estimated runway of 57.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ASMB files for a raise →

👥 Who Owns ASMB

Insiders 30.1% Other 5%+ holders 13.7% Institutions (149 holders) 56.2% Public and other holders 0%
HolderTypeShares% of sharesAs of
GILEAD SCIENCES, INC.
10% owner · +2.30M options
Insider 4,977,089 24.44% 2026-05-26
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 1,604,590 7.88% 2026-06-30
Paradigm BioCapital Advisors LP 5%+ holder (13G) 1,553,748 7.63% 2026-06-30
Dapice Joshua J. 5%+ holder (13G) 1,227,590 6.03% 2025-12-31
Alexander Schornstein
10% owner
Insider 728,113 3.58% 2024-11-22
Jason A Okazaki
CEO and President, Director · +71,100 options
Insider 195,532 0.96% 2026-10-30
William E IV Delaney
Chief Scientific Officer · +25,500 options
Insider 74,035 0.36% 2026-10-30
Nicole S White
Chief Manufacturing Officer · +20,400 options
Insider 59,257 0.29% 2026-10-30
Anuj Gaggar
Chief Medical Officer · +24,200 options
Insider 53,800 0.26% 2026-10-30
John G McHutchison
Director · +11,500 options
Insider 18,347 0.09% 2025-03-31
Jeanette M Bjorkquist
PFO and PAO · +2,500 options
Insider 17,673 0.09% 2026-10-30
Michael Houghton
Director · +11,500 options
Insider 3,202 0.02% 2024-12-30

Share count 20,360,596 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ASMB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASMB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.